Drug details

Afrezza (insulin human inhalation powder)

type of Antidiabetics, Insulins, Antidiabetics, Rapid-Acting Insulins

Afrezza (insulin human) Inhalation Powder is a rapid acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus.

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• nausea,
• loss of appetite,
• dark urine,
• vomiting,
• pale skin,
• lightheadedness,
• shortness of breath,
• tiredness,
• stomach pain,
• yellowing of the skin or eyes (jaundice),
• dizziness,
• swelling,
• weakness,
• unusual tiredness,
• painful or difficult urination,
• shortness of breath, and
• rapid weight gain,
• feeling cold,
• cold hands and feet
• changes in your vision,
• unusual muscle pain,
• pink or red urine,
• slow or irregular heart rate,
• new or worsening urge to urinate,

The following drugs are related to Afrezza, either as a replacement or used together:

• Precose (acarbose)
• Avandia (rosiglitazone maleate)
• Invokana (canagliflozin tablets)
• Cozaar (losartan potassium)
• Lantidra (donislecel-jujn allogeneic pancreatic islet cellular)
• Monopril (fosinopril sodium)
• Monopril HCT (fosinopril sodium-hydrochlorothiazide tablets)
• Glucotrol XL (glipizide extended release)
• Glucovance (glyburide and metformin)
• NovoLog (insulin aspart [rdna origin] inj)
• NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart (rdna origin))
• Mavik (trandolapril)
• Starlix Tablet (nateglinide)
• NovoLog Mix 50/50 (50% insulin aspart protamine suspension and 50% insulin aspart injection)
• Tzield (teplizumab-mzwv injection, for intravenous use)